2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution

Partridge, Savannah C.; Timothy, A.R.; O’Doherty, Michael; Hain, Sharon F.; Rankin, Sheila; Mikhaeel, G.

doi:10.1023/a:1008368330519

Cited by 159 publications

(60 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies in HL patients have shown upstaging in 11-41% and downstaging in 0-28% usingFDG-PET. 13,14,19,20 In our series, 3 modifications (10%) in the treatment strategy according to FDG-PET results affected the extent of radiotherapy fields. A recent report indicates a change in therapeutic strategy in 9% of HL patients after considering the results of PET/CT.…”

Section: Impact Of Fdg Pet On Ann Arbor Staging and Treatmentmentioning

confidence: 69%

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

Ansquer

Hervouet²,

Devillers³

et al. 2008

Haematologica

View full text Add to dashboard Cite

This bicentric study assessed retrospectively the usefulness of 18 F-FDG-PET in the staging of 31 patients with lymphocyte-predominant Hodgkin's disease (LPHD). FDG-PET and conventional explorations (CE) were performed for initial disease (n=25) or recurrence (n= 6). All the 68 involved sites were detected by PET including 5 extra-nodal lesions. Only 43 nodal sites (68%) and one splenic focus were detected by CE. PET changed staging in 9 patients (7 upstaged, 2 downstaged) and radiation fields in 3 patients. These results showed the potential role of PET in the staging of LPHD.

show abstract

Section: Impact Of Fdg Pet On Ann Arbor Staging and Treatmentmentioning

confidence: 69%

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

Ansquer

Hervouet²,

Devillers³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…The meta-analysis by Pakos et al [1] summarising the results of 13 studies comprising a total of 587 patients showed that compared with BMB, the weighted sensitivity and specificity of FDG-PET were 51% and 91%, respectively. In the sub-group analysis, BMB showed better sensitivity in HL (76%) and in aggressive NHL, while FDG-PET gave false negative results in two-thirds of patients with bone marrow involvement in more indolent histological forms of NHL, leading to the conclusion that the role of PET/CT would be complementary [26][27][28][29][30][31][32][33]. Fuster et al [34] investigated the role of FDG-PET vs bone marrow disease in detecting bone marrow disease in patients with HL and NHL and found out that FDG-PET was more sensitive than BMB in HL and NHL with the exception of Grade 1 and 2 follicular lymphomas.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma

Muzahir¹,

Mian²,

Munir³

et al. 2012

The British Journal of Radiology

View full text Add to dashboard Cite

Objective: The aim of the study was to evaluate the potential role of fludeoxyglucose (FDG)-positron emission tomography (PET)/CT in the detection of bone/bone marrow disease in patients with Hodgkin's lymphoma (HL). Methods: We retrospectively reviewed ( Results: There were 122 patients in total-81 (66.4%) were male and 41 (33.6%) were female. The age range was from 6 years to 78 years (mean 35.70 years). PET/CT was reported as negative for bone/bone marrow involvement in 85 (69.7%) patients, while the remaining 37 showed abnormal FDG uptake. The sensitivity of FDG-PET/CT was calculated to be 100%, the specificity was 76.57%, the negative predictive value was 76.57%, the positive predictive value was 29.72% and the diagnostic accuracy was 78.62%. Conclusion:18 F-FDG-PET/CT and BMB are complementary in the evaluation of bone marrow disease.

show abstract

“…Despite these limitations, PET is clearly emerging to have a significant role in the diagnostic evaluation of lymphoma, particularly diffuse large B-cell lymphoma and Hodgkin's disease. Small studies also suggest that the initial management of patients with lymphoma in clinical practice frequently changes based upon PET scan findings [20,21]. A summary of selected published studies of diagnostic PET imaging is in Table 2.…”

Section: Role Of Pet In Diagnostic Imagingmentioning

confidence: 99%

PET Scans in the Staging of Lymphoma: Current Status

Friedberg

Chengazi

2003

The Oncologist

View full text Add to dashboard Cite

Positron emission tomography (PET) is a novel functional imaging technique that provides several inherent advantages over conventional nuclear scintigraphy. Several studies have suggested a role for PET using the positron emitter fluorine-18 in the diagnosis and followup of patients with lymphoma. This review summarizes the existing data evaluating the role of 2-fluoro-2-deoxy-D-glucose (FDG)-PET in both the staging and follow-up of patients with lymphoma. Most studies of PET involve patients with either Hodgkin's disease or diffuse large Bcell non-Hodgkin's lymphoma. PET detects more disease sites above and below the diaphragm on staging of lymphoma than gallium scintigraphy and may have particular utility in the evaluation of the spleen. Moreover, persistently positive PET scans during and after chemotherapy appear to have a high sensitivity for predicting subsequent relapse. A negative PET scan at the end of therapy provides very favorable prognostic information. Persistently positive PET scans at the end of therapy warrant close follow-up or additional diagnostic procedures, since some of those patients may remain in prolonged remission. Clearly, additional studies, including prospective blinded trials and cost-effectiveness analyses, are warranted to determine which subsets of patients with lymphoma ultimately will benefit from this modality.

show abstract

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution

Abstract: Significantly more sites of disease were identified by PET than CT resulting in stage changes and a modification of therapy in 25% of patients. This has important implications not only for current patient management but also for the design of future clinical trials.

Cited by 159 publications

References 22 publications

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma

PET Scans in the Staging of Lymphoma: Current Status

Contact Info

Product

Resources

About